Almudena Laguna Castro

Ms. Almudena Laguna Castro

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2023 in Polymers
Verified
Journal Article
Open access
PDF file
CPCelia López-Manzanara Pérez
Celia López-Manzanara Pérez
NPNorma Sofía Torres Pabón
Norma Sofía Torres Pabón
ACAlmudena Laguna Castro
Almudena Laguna Castro
GDGuillermo Torrado Durán
Guillermo Torrado Durán
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
Simvastatin (SIM) is a potent lipid-lowering drug used to control hyper-cholesterolemia and prevent cardiovascular diseases. SIM presents low oral bioavailability (5%) because of its low aqueous solubility. In this work, polyelectrolyte complexes (PEC) are developed with different chitosan (CS) and carboxymethylcellulose (CMC) ratios that will allow for an increase in the SIM dissolution rate (2.54-fold) in simulated intestinal medium (pH 4.5). Scanning Electron Microscopy (SEM) images revealed highly porous structures. The changes between both complexes, PEC-SIM:CS:CMC (1:1:2) and (1:2:1), were related to the relaxation of the polymer chains upon absorption of the dissolution medium. Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and powder X-ray diffraction (XRPD) studies were used to evaluate the polymer/polymer and drug/polymer interactions on the different PEC-SIM:CS:CMC ratios. In addition, the PEC-SIM:CS:CMC (1:2:1) complex exhibited a high ratio of protonated amino groups (NH3+) and an increase in intramolecular hydrogen bonds, which were correlated with a high expansion of the interpolymer chains and an increase in the SIM dissolution rate. Different kinetic models such as zero-order, first-order, Higuchi and Korsmeyer–Peppas were studied to evaluate the influence of CS/CMC ionic interactions on the ability to improve the release rate of poorly soluble drugs.

16 September 2024 in Gels
Verified
Journal Article
Open access
PDF file
JTJuan J. Torrado
Juan J. Torrado
Brayan J AnayaBrayan J Anaya
Brayan J Anaya
AKAytug Kara
Aytug Kara
BOBaris Ongoren
Baris Ongoren
SRSofía De Esteban Ruiz
Sofía De Esteban Ruiz
DSDolores R Serrano
Dolores R Serrano
Melatonin’s antioxidant properties make it a valuable component in anti-aging semisolid topical products. This study explores the role of Pemulen®, an acrylic-based viscosifying agent, in stabilizing cream-gel formulations. Remarkably, even at low concentrations (0.4%), Pemulen® successfully produced physicochemical stable topical formulations. In this work, the impact of the ratio of the oily phase—comprising olive oil and isopropyl myristate from 0 to 20%—was investigated to understand the internal microstructure effect on skin permeability, rheological properties, and stability. The formulations exhibited pseudoplastic behavior, with a significant positive correlation (p-value < 0.1) between the oily phase ratio, viscosity, spreadability, skin adhesiveness, and permeability. Formulations without the oil phase exhibited greater skin permeability. However, higher oily phase content enhanced viscosity, spreadability, and skin adhesion. Given that melatonin primarily degrades through oxidation, incorporating antioxidant excipients in semisolid formulations is crucial for maintaining its chemical stability. A quality by design (QbD) approach was used to assess the impact of four excipients—(a) DL-α-tocopheryl acetate (0.05%), (b) ascorbic acid (0.1%), (c) ethylene diamine tetraacetic acid (0.1%), and (d) sodium metabisulphite (0.5%)—on melatonin’s stability. Our findings indicate that maintaining the physical stability of the formulation with a 20% oil phase is more critical for protecting melatonin from oxidation than merely adding antioxidant excipients.

26 June 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ACAlmudena Laguna Castro
Almudena Laguna Castro
BABorja Martínez Alonso
Borja Martínez Alonso
VGVíctor Guarnizo-Herrero
Víctor Guarnizo-Herrero
JMJorge Jonathan Nué Martinez
Jorge Jonathan Nué Martinez
Christophe DardonvilleChristophe Dardonville
Christophe Dardonville
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
Background/Objectives: Currently there are very few effective oral antileishmanial treatments. In this study we evaluated a new bis(pyridine-2-carboxamidine) antileishmanial drug (JNII40_base) and its hydrochloride salt (JNII40_HCl). Methods: The characterization studies performed allowed us to determine the crystallinity, hydration water, and presence of hydrogen bonds in these drugs. Different dissolution methods were employed to predict intestinal absorption. A high-performance liquid chromatography–mass spectrophotometry (HPLC-MS/MS) method was developed for the determination of JNII40 in plasma. Results: Pharmacokinetic studies in rats of JNII40_base at 100 and 20 mg/kg, and JNII40_HCl at 20 mg/kg, showed a non-linear pharmacokinetic at high doses. An innovative biorelevant medium of phosphate buffer pH 6.8 with polysorbate 80 at 0.6% (w/v) showed high concentration values for JNII40_base at 30 min, which predicts good intestinal absorption. These results were consistent with the bioavailability data, which exhibited a significant (p < 0.05) increase in maximum plasma concentration (Cmax) and a slight delay in time to maximum (Tmax) compared to JNII40_HCl. Furthermore, the sustained release of JNII40_base in this biorelevant media was related to high plasma concentration values at 24 h (C24h) observed in bioavailability studies. These plasma concentrations of JNII40_base were above the half-maximal inhibitory concentration (IC50) against promastigote and amastigote forms of Leishmania donovani, which is indicative of effectiveness and should reduce the occurrence of drug resistance during treatments. Conclusions: The bioavailability and pharmacokinetic data support the consideration of this drug for further in vivo studies as an oral antileishmanial treatment.

17 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
ACAlmudena Laguna Castro
Almudena Laguna Castro
AGAlicia Guillén
Alicia Guillén
MSMiguel G. Saro
Miguel G. Saro
AMAntonio Matji
Antonio Matji
DSDolores R Serrano
Dolores R Serrano
Low amounts of minoxidil in oral dosage forms are commonly prescribed as anti-alopecic pharmacological treatments. Side effects are usually related to individual susceptibility. However, poor drug content and mass uniformity can lead to a potential risk of overdosing, and higher chances to experience side effects. The impacts of four formulation variables on drug content and mass pharmaceutical quality attributes were studied with an experimental design at two levels. The first variable (A) was the particle size of the direct compression microcrystalline cellulose (MCC) used as a diluent (Avicel® PH 101 vs. LP 200). The second variable (B) was the type of production process (direct filling vs. wet granulation). The third variable (C) was the particle size of riboflavin added as a color mixture indicator agent (granular vs. milled). The fourth variable (D) was the type of oral solid dosage form (capsule vs. tablet). In half of the formulations, the mean minoxidil content and minoxidil uniformity were out of the specification limits of the Pharmacopoeia, demonstrating the importance of carefully selecting the excipients as well as the utilized process when manufacturing low oral dosage minoxidil formulations. The best minoxidil content uniformity was achieved when using MCC LP 200, wet granulation, granular riboflavin, and capsules. However, tablets are the recommended dosage form when utilizing Avicel® PH 101 or direct filling. Meeting these criteria, the content and mass uniformity are more likely to meet the specification limits of the Pharmacopeia. Techniques such as NIR spectroscopy should be implemented to control the quality of extemporaneous compounding formulations with a low dose of active ingredient.

10 March 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ACAlmudena Laguna Castro
Almudena Laguna Castro
ASAdriana Oliveira Santos
Adriana Oliveira Santos
Márcio José de Abreu Marques RodriguesMárcio José de Abreu Marques Rodrigues
Márcio José de Abreu Marques Rodrigues
Gilberto AlvesGilberto Alves
Gilberto Alves
Christophe DardonvilleChristophe Dardonville
Christophe Dardonville
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
Different self-emulsifying drug delivery systems (SEDDS) were developed to improve the poor oral bioavailability of the bis(pyridine-2-carboxamidine) compound JNII40, a promising new oral antileishmanial drug. Solubility, Particle size, transmission microscopy, precipitation, and permeability assays were used to characterize the formulations. Different pharmacokinetic parameters such as maximum concentration (Cmax), concentration at 24 h (C24h), half-life (t1/2), bioavailability and plasma concentrations above IC50 value were used to evaluate a possible relationship with the efficacy of these formulations. SEDDS with hydrophilic solvents F1 showed higher solubility values (4.09 ± 0.65 mg/mL) and rapid precipitation in simulated intestinal medium. However, SEDDS with less hydrophilic solvents (F6) showed lower solubility (1.69 ± 0.07 mg/mL) but exhibited high supersaturation concentrations at pH 6.8. Permeability assays intestinal tissue demonstrated that SEDDS F6 exhibited a high increase in intestinal absorption (2.51-fold at 2 h compared to JNII40). These good results were related to the absence of transcutol® HP and a high Capryol® 90 ratio in its composition. Pharmacokinetic results for SEDDS F6 given as a single oral dose of 2 mg/kg of JNII40 showed a significant increase in the Cmax (1.28-fold), C24h (1.18-fold) and bioavailability (1.21-fold) compared to the active ingredient. The SEEDS formulation showed plasma concentrations up to 3 × IC50 against L. donovani intracellular amastigotes during 24 h. The bioavailability improvement of JNII40 with SEDDS displaying high C24h and t1/2 values is relevant. Hence, these SEDDS should be considered as drug delivery system for oral administration of this antileishmanial drug.